Clinical Trials Browser

Pdgfra-Associated Chronic Eosinophilic Leukemia, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Pyloric Stenosis, Hypertrophic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04767802 2024-03-18

PACIFIC

Phase 2 Completed

20 enrolled

Myeloid

Polycythemia Vera

NCT05074550 2023-07-24

Safety Evaluation Study for Patients With Polycythemia Vera

Phase 1 Unknown

6 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT02124746 2023-06-18

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Phase 2 Completed

87 enrolled 17 charts

Myeloid

Hematologic Diseases, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04896112 2023-06-18

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Polycythemia Vera, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Phase 1/2 Withdrawn

Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT01423851 2022-03-09

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Phase 1/2 Completed

77 enrolled 33 charts

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01981850 2022-01-05

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Phase 2 Completed

125 enrolled 38 charts

Myeloid

Fibrosis, Polycythemia Vera, Primary Myelofibrosis

NCT03287245 2021-12-08

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Phase 2 Terminated

27 enrolled 28 charts

Myeloid

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02055781 2021-11-18

PAC326

Phase 3 Terminated

311 enrolled 12 charts

Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT02038036 2021-07-20

RESPONSE-2

Phase 3 Completed

149 enrolled 19 charts

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02218047 2021-06-01

CONTI-PV

Phase 3 Completed

170 enrolled

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera

NCT04283526 2021-03-04

Study of Select Combinations in Adults With Myelofibrosis

Phase 1 Withdrawn

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01773187 2020-09-29

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Phase 3 Terminated

327 enrolled 11 charts

Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT03121599 2020-08-11

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Phase NA Terminated

3 enrolled

Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT03669965 2020-07-31

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Phase 2 Unknown

20 enrolled

Myeloid

Polycythemia Vera

NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Phase 2 Terminated

39 enrolled

Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Phase 1/2 Completed

50 enrolled 23 charts

Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT00606307 2019-12-03

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Phase 2 Completed

29 enrolled 8 charts

Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00928707 2019-10-31

PV

Phase 2 Completed

45 enrolled 10 charts

Myeloid

Polycythemia Vera

NCT01901432 2019-07-30

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Phase 1/2 Completed

48 enrolled 28 charts

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT02292446 2019-07-18

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Phase 3 Completed

161 enrolled 14 charts

Myeloid

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

Clinical Trials

CINC424A2X01B Rollover Protocol

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

IMG-7289-CTP-203

HU-F-AIM

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

MK-3543-017

GIV-IN-PV

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

SLN

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

A Study of GLB-001 in Patients With Myeloid Malignancies

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

VERIFY

THRIVE

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

PV

Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)

A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

A Study to Evaluate P1101 in Japanese PV Patients

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

PACIFIC

Safety Evaluation Study for Patients With Polycythemia Vera

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

PAC326

RESPONSE-2

CONTI-PV

Study of Select Combinations in Adults With Myelofibrosis

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

PV

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.